ArticlePigment cell & melanoma research2015
Riluzole is a radio-sensitizing agent in an in vivo model of brain metastasis derived from GRM1 expressing human melanoma cells.
Article in Pigment cell & melanoma research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- 3D Glioblastoma Molecular Responses to Carbon Dot-Delivered Riluzole Probed by Synchrotron FTIR.Analytical chemistry · 2026Article
- Single-cell in situ mapping of glioblastoma and astrocyte cell lines treated with a carbon dot-mediated riluzole nanotherapeutic agent: a live-cell µFTIR and soft X-ray tomography approach.Journal of nanobiotechnology · 2025Article
- Review
- Radiotherapy in Preclinical Models of Brain Metastases: A Review and Recommendations for Future Studies.International journal of biological sciences · 2024Review
- ACell reports. Medicine · 2023Article
- Review
- Riluzole: A neuroprotective drug with potential as a novel anti‑cancer agent (Review).International journal of oncology · 2021Review
- Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines.Cancer research · 2020Review
- Review
- Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent.Frontiers in cell and developmental biology · 2020Article
- Riluzole Enhances the Response of Human Nasopharyngeal Carcinoma Cells to Ionizing Radiation via ATM/P53 Signalling Pathway.Journal of Cancer · 2020Article
- The Evolving Landscape of Brain Metastasis.Trends in cancer · 2018Review
- Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells.Oncotarget · 2017Article
- Metabotropic glutamate receptors in cancer.Neuropharmacology · 2017Review
- Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by Riluzole.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Approximately 50% of patients having metastatic melanoma develop brain metastases during the course of their illness. Evidence exists that melanoma cells have increased aptitude for the repair of sublethal DNA damage caused by ionizing radiation therapy. To address the radio-resistance of melanoma, many groups adopted radiotherapy schedules that deliver larger daily fractions of radiation, but due to the risk of neurotoxicity, these large fractions cannot be delivered to the whole brain for patients with brain metastases. Here, we used orthotopic implanted GRM1 expressing human melanoma cell xenografts in mice, to demonstrate that animals receiving concurrent glutamate signaling blockade (riluzole) and radiation led to a decrease in intracranial tumor growth compared to either modality alone. These preclinical results suggest riluzole may cause radio-sensitization that offers enhanced efficacy for a subset of human melanoma patients undergoing radiotherapy for brain metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.